Vaxcyte (PCVX) Current Leases (2019 - 2026)
Vaxcyte (PCVX) posted quarterly Current Leases of $6.1 million for Q1 2026, down 0.7% year-over-year from $6.1 million in Q1 2025, and down 0.64% quarter-over-quarter from $6.1 million in Q4 2025.
Vaxcyte (PCVX) Current Leases (2019 - 2026) Analysis & Trends
Vaxcyte (PCVX) has reported Current Leases for 7 consecutive years, with $6.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Leases fell 0.7% year-over-year to $6.1 million; the TTM figure through Mar 2026 stood at $6.1 million (down 0.7% YoY), while the FY2025 annual figure was $6.1 million, up 3.96% from the prior year.
- Current Leases slipped to $6.1 million in Q1 2026 per PCVX's latest filing, from $6.1 million in the prior quarter.
- Across five years, Current Leases topped out at $9.6 million in Q3 2024 and bottomed at $5.8 million in Q3 2025.
- Historically, Current Leases has averaged $6.5 million across 5 years, with a median of $6.1 million in 2025.
- Annual changes were most pronounced in 2022 — Current Leases soared 948.29% — and 2025, when it slumped 40.12%.
- Vaxcyte's Current Leases stood at $5.9 million in 2022, then increased by 20.36% to $7.1 million in 2023, then fell by 17.18% to $5.9 million in 2024, then advanced by 3.96% to $6.1 million in 2025, then declined by 0.64% to $6.1 million in 2026.
- Business Quant data shows PCVX's Current Leases at $6.1 million in Q1 2026, $6.1 million in Q4 2025, and $5.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 11.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 16.75 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 21.95 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 2.24 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 45.93 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.27 Mn |
| 10 | Vaxcyte | 8.41 Bn | 8.41 Bn | - | 6.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.51 Mn |
| Mar 31, 2026 | 6.09 Mn |
| Dec 31, 2025 | 6.12 Mn |
| Sep 30, 2025 | 5.77 Mn |
| Jun 30, 2025 | 6.30 Mn |
| Mar 31, 2025 | 6.13 Mn |
| Dec 31, 2024 | 5.89 Mn |
| Sep 30, 2024 | 9.64 Mn |
| Jun 30, 2024 | 7.29 Mn |
| Mar 31, 2024 | 7.20 Mn |
| Dec 31, 2023 | 7.11 Mn |
| Sep 30, 2023 | 6.03 Mn |
| Jun 30, 2023 | 5.99 Mn |
| Mar 31, 2023 | 5.95 Mn |
| Dec 31, 2022 | 5.91 Mn |
| Sep 30, 2022 | 6.43 Mn |
| Jun 30, 2022 | 6.64 Mn |
| Mar 31, 2022 | 6.58 Mn |
| Dec 31, 2021 | 5.28 Mn |
| Sep 30, 2021 | 613,000.00 |